I am an drug development consultant with extensive experience in bringing new [505(b)(1)] and repurposed [5050(b)(2)] drugs to market. I have an undergraduate degree in pharmaceutical sciences from the University of British Columbia, a doctor of pharmacy degree from the SUNY, Buffalo and an MBA from the California Institute of Advanced Management.
Presently I am a drug development consultant to investment banks, law firms and pharmaceutical companies. My prior experience, in chronologic order includes: (i) V.P., Clinical Development at Cadence Pharmaceuticals; (ii) CSO of TheraQuest Biosciences; (iii) V.P., Global Clinical Drug Development and Therapeutic Leader, Analgesia & Rheumatology at Scirex Corporation (now Premier Research), a boutique CRO; and (iv) Director, Clinical Research at Purdue Pharma.
I have been an invited speaker at FDA, FDA Advisory Committees, NIH, and national scientific meetings. I have designed drug development programs and clinical trials on several dozen new [505(b)(1)] and repurposed [5050(b)(2)] compounds. I am on the editorial board of the Journal of Opioid Management. I have published ≥ 170 abstracts and manuscripts in leading medical journals, including the Lancet, JAMA, Journal of Clinical Oncology, Cancer, Journal of Clinical Pharmacology, Pain and Clinical Pharmacology & Therapeutics. My publications have focused on acute, cancer, chronic and neuropathic pain, cancer supportive care and clinical trials methodology.